# A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies

> **NCT05780034** · PHASE1 · RECRUITING · sponsor: **Accutar Biotechnology Inc** · enrollment: 60 (estimated)

## Conditions studied

- Relapsed/Refractory B-cell Malignancies

## Interventions

- **DRUG:** AC676

## Key facts

- **NCT ID:** NCT05780034
- **Lead sponsor:** Accutar Biotechnology Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-06-20
- **Primary completion:** 2026-03-31
- **Final completion:** 2026-05-31
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-10-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05780034

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05780034, "A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT05780034. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*